Photo by jeremybishop from unsplash
The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)‐positive tumors is based on nodal status. The authors’ objective was to evaluate pathologic nodal disease… Click to show full abstract
The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)‐positive tumors is based on nodal status. The authors’ objective was to evaluate pathologic nodal disease (pathologic lymph node‐positive [pN‐positive] and pathologic lymph node‐positive after preoperative systemic therapy [ypN‐positive]) rates in patients who had clinical T1–T2 (cT1–cT2)N0M0, HER2‐positive breast cancer treated with upfront surgery or neoadjuvant chemotherapy (NAC).
Keywords:
epidermal growth;
factor receptor;
growth factor;
human epidermal;
cancer;
systemic therapy
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!